SCHEMBL984930

SCHEMBL984930

CN(C)c1nc(C(=O)O)c(-c2cccc(Cl)c2)s1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 3/20 0.49
HCRTR1 O43613 3/20 0.47
HCRTR2 O43614 3/20 0.47
MDM2 Q00987 4/20 0.44
KMT2A Q03164 2/20 0.43
KMO O15229 2/20 0.42
DHODH Q02127 1/20 0.41
NPC1 O15118 2/20 0.41
POLB P06746 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
PKM P14618 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL982257 0.88 PIN1 (0.45) PIN1HCRTR1HCRTR2MDM2KMT2A
SCHEMBL985026 0.86 PIN1 (0.46) PIN1HCRTR1HCRTR2MDM2KMT2A
SCHEMBL1340321 0.85 PIN1 (0.49) PIN1HCRTR1HCRTR2MDM2KMT2A
SCHEMBL980993 0.84 ALDH1A1 (0.47) PIN1HCRTR1HCRTR2KMT2ANPC1
SCHEMBL980677 0.84 PIN1 (0.50) PIN1KMOSMN1; SMN2
SCHEMBL271164 0.82 PIN1 (0.59) PIN1HCRTR1HCRTR2MDM2KMT2A
SCHEMBL980763 0.82 PIN1 (0.51) PIN1HCRTR1HCRTR2NPC1RAB9A
SCHEMBL3009703 0.81 PIN1 (0.50) PIN1HCRTR1HCRTR2MDM2KMT2A
SCHEMBL1971006 0.80 KDM4E (0.51) PIN1MDM2KMT2AKMONPC1
SCHEMBL8043074 0.79 KMT2A (0.45) HCRTR1HCRTR2KMT2ANPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236801-B2 2-aza-bicyclo[2.2.1]heptane derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-08-07 US disclosed
EP-2247586-B1 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2012-04-25 EP disclosed
CN-101965343-A 2-aza-bicyclo[2.2.1]heptane derivatives ACTELION PHARMACEUTICALS LTD 2011-02-02 CN disclosed
US-20110009401-A1 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-01-13 US disclosed
EP-2247586-A1 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-11-10 EP disclosed
WO-2009104155-A1 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009401-A1 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES HCRTR2, HCRTR1, HCAR2 PIN1 3660/4885HCRTR1 2/4885HCRTR2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.